LYON, France --(BUSINESS WIRE)--
Adocia (Paris:ADOC) (Euronext Paris: FR0011184241 – ADOC), a clinical stage biopharmaceutical company focused on diabetes treatment with innovative formulations of approved proteins, announces today that it received the EY Global Company Award for the Auvergne Rhône-Alpes region, during the 24th EY Entrepreneur of the Year event in Lyon.
The award ceremony, which was co-organized by the newspapers l’Express, took place on Tuesday September 20th in the reception rooms of Lyon’s City Hall, in the presence of David Kimelfeld, First Vice President of the Lyon Métropole and of Emmanuel Imberton, President of the Chamber of Commerce and Industry of Lyon Metropole St Etienne Roanne.
Adocia received the Global Company Award, which recognizes a company who is a leader on its market and whose strategy and culture are international, with at least 25% of its turnover made overseas.
“We are delighted to receive the EY Global Company Award. We would like to share it with the teams of Adocia who daily contribute to the development of the company.” said Gérard Soula, President and CEO of Adocia. “This award also recognizes our strategy focused on innovation in diabetes treatment and our internationally reknowned expertise.”
For more than 20 years, the EY Entrepreneur of the Year Award has been first presented to companies in a regional competition. Regional laureates then compete for the National Award in their respective category. The EY Entrepreneur of the Year Award benefits from the financial support of its partners Group Edmond the Rothschild, Verlingue, Bpifrance and the media support of Les Echos and Widoobiz.
Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins. Adocia’s insulin formulation portfolio, featuring four clinical-stage products and one preclinical product, is among the largest and most differentiated in the industry.
The proprietary BioChaperone® technological platform is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. Adocia customizes BioChaperone to each protein for a given application in order to address specific patient needs.
Adocia’s clinical pipeline includes four novel insulin formulations for the treatment of diabetes: two ultra-rapid formulations of insulin analogs (BioChaperone Lispro U100 and U200), a rapid-acting formulation of human insulin (HinsBet U100) and a combination of insulin glargine and a rapid-acting insulin analog (BioChaperone Combo). Adocia is also developing an aqueous formulation of human glucagon (BioChaperone Glucagon), two combinations of insulin glargine with GLP-1s (BioChaperone Glargine Dulaglutide and BioChaperone Glargine Liraglutide) and a concentrated, rapid-acting formulation of human insulin (HinsBet U500), all of which are in preclinical development.
In December 2014, Adocia signed a partnership with Eli Lilly for the development and commercialization of the BioChaperone Lispro projects.
Adocia aims to deliver “Innovative medicine for everyone, everywhere.”
To learn more about Adocia, please visit us at www.adocia.com
(c)Business Wire. All of the news releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire's members, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.